Pharmacokinetics and tolerability of aminosidine after repeated administrations using an optimal dose regimen in healthy dogs and in dogs with leishmaniosis

Activity of a novel sulfonamide compound 2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide against Leishmania donovani

“… 3 The toxicity of miltefosine includes its teratogenic potential and its long half-life (~150 hours), which may facilitate the emergence of resistance, 4 , 5 and aminoglycosides-related adverse effects, including elevated hepatic transaminases, ototoxicity, nephrotoxicity, and pain at the injection site. 6 , 7 Drug efficacy against different clinical isolates is variable, and the emergence of acquired resistance to the pentavalent antimonials is a major concern, particularly in the state of Bihar, India, where 64% of cases show resistance to antimonials. Similarly, emerging resistance to amphotericin B (AmB) in Bihar emphasizes the need for new and effective treatments.…”

Comparative study of the efficacy and safety between aminosidine (paromomycin) and meglumine antimonate for the treatment of canine leishmaniosis due to Leishmania infantum

“…Accordingly, a systematic review of studies published until 2004, concluded that there was fair evidence against recommending aminosidine at doses higher than 20 mg/kg and fair evidence for recommending it at the dosage regimen of 5 mg/kg, twice daily . However, more recent studies showed that subcutaneous (SC) administration of aminosidine at an optimized dose regimen (15 mg/kg, once daily) for 21 days, results in effective peak plasma concentrations (Athanasiou et al, 2014) and leads, at least on a short-term basis, to clinical and clinicopathological improvement and reduction of parasitic load, without side effects .…”